![]() ![]() Both catheters will be on display as part of Teleflex’s hands-on workshops during CTO Plus: Complex CTO & Higher Risk PCI, February 23-24 at the New York Marriott Marquis in Times Square. The GuideLiner ® Coast™ Catheter is currently in a limited market release phase, with full market release anticipated later this year. “The Triumph™ Catheter and the GuideLiner ® Coast™ Catheter reflect our focus on providing physicians with new choices and technologies engineered to address unmet clinical needs, personal preference and technique, and the challenges of complex anatomy.” “Teleflex is committed to providing more options in the cath lab to help interventionalists address the specific needs of their patients,” said Scott Holstine, President and General Manager of Teleflex’s Interventional business unit. 1 Earlier this year, the GuideLiner ® Coast™ Catheter was first used in a clinical procedure at the UW Medicine Heart Institute in Seattle, Washington. The GuideLiner ® Coast™ Catheter adds a hydrophilic option to Teleflex’s market-leading guide extension portfolio-anchored by the flagship GuideLiner ® V3 Catheter-enabling physicians to select the level of deliverability and backup support needed for specific cases. “The Triumph™ Catheter’s nitinol ports and cage bring navigation and control to a new level, and I am excited that Teleflex will enable interventional cardiologists to readily access this important technology.” “In complex cases, the ability to better navigate tortuous anatomy has long been a challenge,” said Dr. Designed in collaboration with Bill Nicholson, MD, Director of Interventional Cardiology at Emory Healthcare, Atlanta, GA, the Triumph™ Catheter features a unique design with six wire exit ports for precise wire advancement and clear visualization. The Triumph™ Catheter is the latest addition to the Teleflex family of catheters, which includes the GuideLiner ® V3 Catheter, TrapLiner ® Catheter, and Turnpike ® Catheters. Food and Drug Administration (FDA) 510(k) clearance of the Triumph™ Catheter, and the first clinical use of GuideLiner ® Coast™ Catheter. 22, 2023 (GLOBE NEWSWIRE) - Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced key milestones in the release of two new catheters: the U.S. The events for both extension catheters mainly involved the inability to pass equipment through or damage to percutaneous coronary intervention (PCI) devices in the extension catheter, extension catheter fracture, coronary artery dissection and perforation and, occasionally, the death of the patients.Ĭomplications Guide extension catheter Percutaneous coronary intervention.Ĭopyright © 2019 Elsevier Inc. There were more reports on Guidezilla-related events during the search period. To assess the reported complications and event modes for the GuideLiner and Guidezilla extension catheters, the US Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database was queried. Of the 408 cases with reported Guidezilla-related issues, 53 (13%) involved inability to pass or damaged PCI devices into the Guidezilla catheter, 117 (29%) involved inability to advance the Guidezilla catheter to the target lesion, 59 (14%) involved kinked Guidezilla catheter, mostly because of partial or complete catheter fracture upon further investigation, 164 (40%) involved a broken Guidezilla catheter, 10 (2.5%) involved coronary artery dissection, 2 (0.5%) involved coronary artery perforation, 1 (0.2%)involved aortic dissection, 1 (0.2%) involved thrombosis formation, and 1 (0.2%) involved no-reflow phenomenon.įindings from the MAUDE database highlight the complications and modes of events associated with the use of GuideLiner and Guidezilla extension catheters. ![]() Of the 65 cases with reported GuideLiner-related issues, 15 (23%) involved the inability to pass equipment through or damage to percutaneous coronary intervention (PCI) devices in the GuideLiner catheter, 38 (58%) involved GuideLiner catheter fracture, 9 (14%) involved coronary artery dissection, 2 (3%) involved coronary artery perforation, and 1 (1.5%) involved thrombus formation in the catheter. The US Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database was queried for reported events. We aimed to assess the reported complications and event modes for the GuideLiner and Guidezilla extension catheters.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |